| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/18/2002 | WO2002030454A1 Methods for controlling the lysis of coagulated blood with apolipoprotein e4 phenotype |
| 04/18/2002 | WO2002030441A2 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 04/18/2002 | WO2002030435A1 Treatment of t cell disorders |
| 04/18/2002 | WO2002030429A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 04/18/2002 | WO2002030426A1 Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| 04/18/2002 | WO2002030424A1 Modified prodrug forms of ap/amp |
| 04/18/2002 | WO2002030419A1 Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| 04/18/2002 | WO2002030417A1 Medicinal suspensions containing branched amino acids |
| 04/18/2002 | WO2002030412A1 Compositions containing tryptamines, carotenoids and tocotrienols having synergistic antioxidant |
| 04/18/2002 | WO2002030410A2 Suppression of cyclin kinase activity for prevention and treatment of infections |
| 04/18/2002 | WO2002030408A2 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 04/18/2002 | WO2002030406A2 Use of antagonists or partial agonists of 5ht1a receptors for the preparation of a medicament for treatment and prevention of gastrointestinal diseases |
| 04/18/2002 | WO2002030405A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 04/18/2002 | WO2002030396A1 Medication delivery devices |
| 04/18/2002 | WO2002030351A2 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | WO2002030320A2 Stimulation of thymus for vaccination development |
| 04/18/2002 | WO2002030268A2 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
| 04/18/2002 | WO2002030257A2 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | WO2002014499A9 Claudin polypeptides |
| 04/18/2002 | WO2002011742A3 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 04/18/2002 | WO2002009815A3 New pharmaceutical composition |
| 04/18/2002 | WO2002009814A3 New use of lipase inhibitors |
| 04/18/2002 | WO2002009682A3 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure |
| 04/18/2002 | WO2002007721A3 Use of cox-2 inhibitors for preventing immunodeficiency |
| 04/18/2002 | WO2002003995A3 Treatment of male sexual dysfunction |
| 04/18/2002 | WO2002000201A3 Method for preparing a composition |
| 04/18/2002 | WO2001096353A3 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES |
| 04/18/2002 | WO2001093806A3 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS |
| 04/18/2002 | WO2001087272A3 Encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 04/18/2002 | WO2001087229A3 Treating infections |
| 04/18/2002 | WO2001083744A3 Natrium-calcium exchanger protein |
| 04/18/2002 | WO2001082969A3 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent |
| 04/18/2002 | WO2001081574A3 Regulation of nf-at interacting protein nip 45 variant |
| 04/18/2002 | WO2001081409A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 04/18/2002 | WO2001072777A3 Human transcription factors |
| 04/18/2002 | WO2001066595A3 Human fgf-23 gene and gene expression products |
| 04/18/2002 | WO2001064876A3 Human schizophrenia gene |
| 04/18/2002 | WO2001061007A9 Fibroblast growth factor-23 molecules and uses thereof |
| 04/18/2002 | WO2001060400A3 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/18/2002 | WO2001060345A3 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
| 04/18/2002 | WO2001058916A3 Antibodies to ccr5 |
| 04/18/2002 | WO2001053330A3 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them |
| 04/18/2002 | WO2001045691A3 Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| 04/18/2002 | WO2001040271A3 Cancer associated antigens and uses therefor |
| 04/18/2002 | WO2001034202A3 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 04/18/2002 | WO2001025437A3 Growth factor polypeptides and nucleic acids encoding same |
| 04/18/2002 | WO2000071752A9 Assay for the detection of paclitaxel resistant cells in human tumors |
| 04/18/2002 | WO2000070341A9 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 04/18/2002 | WO2000067793A9 Death domain containing receptor 4 |
| 04/18/2002 | WO2000066106A9 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 04/18/2002 | US20020045759 E.g., N-(2-Phenylsulfonyl-1-ethyl)-3-(4-Cyanophenyl)-2,3-dihydro-imidazo(2,1 -b)thiazole-5-carboxamide hydrochloride; treating cancer, neurofibromin benign proliferative disorder, retinal vascularization, and hepatitis delta |
| 04/18/2002 | US20020045734 Geneticaly engineered polypeptide for use drug delivery tools |
| 04/18/2002 | US20020045667 Non-toxic antimicrobial compositions and methods of use |
| 04/18/2002 | US20020045665 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 04/18/2002 | US20020045659 Use, in cosmetic preparations, of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs |
| 04/18/2002 | US20020045656 NMDA receptor NR2B subunit antagonist and a neutrophil inhibiting factor; therapies that reduce or prevent neuronal dysfunction and death after ischemic, hypoxic or traumatic CNS insult |
| 04/18/2002 | US20020045648 Therapeutic compositions comprising excess enantiomer |
| 04/18/2002 | US20020045647 N-linked urea or carbamate of heterocyclic thioester hair growth compositons and uses |
| 04/18/2002 | US20020045646 Pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors with fast acting buffer; gastric acid stability for enteral administration |
| 04/18/2002 | US20020045638 Method of treating estrogen receptor positive carcinoma |
| 04/18/2002 | US20020045636 Administering a drug composition comprising an opioidergic agent (e.g. an opiate antagonist, an opiate having mu-agonist activity, or a combination) and an insulin secretagogue |
| 04/18/2002 | US20020045632 Synergistic antitumor mixture of tegafur, uracil and folinic acid to potentiate coadministered oxaliplatin; colorectal cancer |
| 04/18/2002 | US20020045621 A mobile ionophore composition effective to modulate APP catabolism without substantially altering the viability of APP-containing cells; inhibits amyloid deposition; Alzheimer's disease; nontoxic |
| 04/18/2002 | US20020045616 Lactam inhibitors of FXa and method |
| 04/18/2002 | US20020045613 1-aroyl-piperidinyl benzamidines |
| 04/18/2002 | US20020045608 Drug addiction, drug dependence |
| 04/18/2002 | US20020045593 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
| 04/18/2002 | US20020045590 Inhibition of interaction of PSD93 and PSD95 with nNOS and NMDA receptors |
| 04/18/2002 | US20020045585 Cytoskeletal active agents for glaucoma therapy |
| 04/18/2002 | US20020045580 Compositions for raising uric acid levels and methods of using same |
| 04/18/2002 | US20020045577 Human schizophrenia gene |
| 04/18/2002 | US20020045572 Method of treating the syndrome of type 2 diabetes in humans |
| 04/18/2002 | US20020045566 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | US20020045229 Nucleotide sequences coding membrane protein for use inthe treatment of epilepsey, arrhythmia, and pain in humans |
| 04/18/2002 | US20020045206 Contacting the cells with a trophic amount of a ptc therapeutic for promoting survival of substantia nigra neuronal cells |
| 04/18/2002 | US20020045201 Sreening drugs for use in treatment of nervous system disorders; obtain protein sample, mix with modulator, monitor complex formation, compare to control, adjustment in concentration of preferential complex indicates modulator |
| 04/18/2002 | US20020045166 Peptides; for use as tools in gene therapy |
| 04/18/2002 | US20020045162 Identification of viral agents in breast ducts and antiviral therapy therefore |
| 04/18/2002 | US20020044981 Mixture of polyunsaturated fatty acids containing linoleic, gamma-linolenic, alpha-linolenic, and stearidonic acid; antilipemic agent, antioxidant and/or antidiabetic agent. |
| 04/18/2002 | US20020044966 Pharmaceutical formulations containing an opioid and an alpha-agonist |
| 04/18/2002 | US20020044961 Nutritional formulations |
| 04/18/2002 | US20020044953 Rapid effect, at a low concentration and/or with a low rate of application; nontoxic |
| 04/18/2002 | US20020044932 Monocyte chemoattractant activity of galectin-3 |
| 04/18/2002 | US20020044923 Modulating immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy |
| 04/18/2002 | US20020044920 Administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide |
| 04/18/2002 | US20020044919 Combinations and methods for treating neoplasms |
| 04/18/2002 | DE10050995A1 New benzylic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050994A1 New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | CA2462073A1 Hematopoietic stem cell gene therapy |
| 04/18/2002 | CA2462046A1 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | CA2462027A1 Stimulation of thymus for vaccination development |
| 04/18/2002 | CA2425910A1 Treatment and prevention of gastrointestinal disease using antagonists or partial agonists of 5ht1a receptors |
| 04/18/2002 | CA2425815A1 Treatment of t cell disorders |
| 04/18/2002 | CA2425779A1 Compositions that inhibit proliferation of cancer cells |
| 04/18/2002 | CA2425771A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | CA2425767A1 Lipocalins |
| 04/18/2002 | CA2425632A1 Agents for the treatment of viral infections |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |